Recent Blog Posts

View Post: Adverse Heart Effects of Rofecoxib May Have Been Identified Years ...
25 Nov 2009 by Bankix Systems Blog  
Clinical trial data indicated an association between the anti-inflammatory medication rofecoxib and cardiovascular risk as early as December 2000, before the product was taken off the market in September 2004, according to a report in ...
View Blog: Bankix Systems Blog - http://bankixsystems.blogspot.com/

---

View Post: Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial ...
23 Nov 2009 by Ross, J. S., Madigan, D., Hill, K. P.,...  
Background In September 2004, rofecoxib was voluntarily withdrawn from the worldwide market. Our objective was to determine whether and when analysis of published and unpublished placebo-controlled trials could have revealed ...
View Blog: Archives of Internal Medicine current issue - http://archinte.ama-assn.org/

---

View Post: Analysis of rofecoxib trial data suggests that cardiovascular risk ...
24 Nov 2009
Pooled data from all placebo-controlled trials involving rofecoxib suggests that there may have been a statistically significant signal of increased cardiovascular risk up to 3.5 years before it was actually withdrawn. ...
View Blog: NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/

---

View Post: Rofecoxib's adverse heart effects may have been identified years ...
24 Nov 2009 by Ani  
WASHINGTON - A new American report suggests that clinical trial data had pointed out the association between the anti-inflammatory drug rofecoxib and cardiovascular risk nearly eight years ago. The report notes that Rofecoxib had ...
View Blog: Health News - http://blog.taragana.com/health/

---

View Post: Vioxx (Rofecoxib) Dangers Known Earlier
23 Nov 2009 by Zamp  
Before the headlines hit about the dangers of using Vioxx (rofecoxib), researchers were already aware, say news reports. Vioxx, a non-steroidal anti-inflammatory (NSAID), was made by Merck & Co. Inc., and introduced to the American ...
View Blog: Bio Topics - http://biotopics.zampbioworld.org/

---

View Post: Postmarketing lessons from Vioxx
23 Nov 2009
"All along, Merck insisted there was no evidence that rofecoxib increased cardiovascular risk in comparison with placebo, until the APPROVE study," Ross explained to heartwire. "Our new analysis shows how the placebo-control-only ...
View Blog: theHeart.org - http://www.theheart.org/

---